Published in final edited form as:

Bioorg Med Chem Lett. 2009 December 15; 19(24): 6962–6965. doi:10.1016/j.bmcl.2009.10.063.

Synthesis and Evaluation of a Thio Analogue of Duocarmycin SA

Karen S. MacMillan^a, James P. Lajiness^a, Carlota Lopez Cara^b, Romeo Romagnoli^b, William M. Robertson^a, Inkyu Hwang^a, Pier Giovanni Baraldi^{b,*}, and Dale L. Boger^{a,*}

^aDepartment of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037 USA

^bDipartimento di Scienze Farmaceutiche, Università degli Studi di Ferrara, via Fossato di Mortara 17/19, 44100, Ferrara, Italy

Abstract

The design, synthesis, and preliminary evaluation of methyl 1,2,8,8a-tetrahydrocyclopropa[*c*]thieno [3,2-*e*]indol-4-one-6-carboxylate (CTI) derivatives are detailed representing a single atom change (NH→S) embedded in the duocarmycin SA alkylation subunit.

Duocarmycin SA (**1**, IC₅₀ = 10 pM)¹ is among the most potent members of a class of antitumor antibiotics that also include duocarmycin A (**2**),² yatakemycin (**3**),³ and CC-1065 (**4**).⁴ Each derives its properties from a characteristic sequence-selective alkylation of duplex DNA,^{5–9} in which a stereoelectronically controlled adenine N3 addition to the least substituted carbon of the activated cyclopropane occurs within selected minor-groove AT-rich sites. Extensive investigations on the natural products in this class as well as their synthetic analogues have defined key and subtle features that contribute to their properties.^{9,10} Most notable of these are the structural features that contribute to the AT-rich noncovalent binding selectivity dominating the alkylation selectivity,¹¹ those that are responsible for the source of catalysis for the DNA alkylation reaction,^{12,13} and those that subtly impact the unusual and intrinsic stability of their alkylation subunits.^{9,13–16}

In a recent study,¹⁷ the rational design of a modified CC-1065 alkylation subunit was conducted with the goal of increasing its chemical stability and resulting biological potency and provided more potent analogues of the natural product. Thus, the replacement of the pyrrole NH in the CC-1065 alkylation subunit with a larger, more electron-withdrawing sulfur atom had the predicted and desired effect of reducing the solvolytic reactivity of the alkylation subunit, and ultimately increasing the cytotoxic potency of the corresponding CC-1065 analogue (IC₅₀ = 7 pM vs 20 pM) to levels on par with duocarmycin SA (10 pM). Herein, we report the extension of these studies to an analogous alkylation subunit pyrrole NH to S modification of the duocarmycin SA alkylation subunit,¹⁸ replacing a single atom in **1** to generate **7** (Figure 2).

© 2009 Elsevier Ltd. All rights reserved.

*Corresponding authors: Phone: 858-784-7522, Fax: 858-784-7550, boger@scripps.edu (D. Boger); Phone: 39-0532-455921, Fax: 39-0532-455953, baraldi@unife.it (P. Baraldi).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Data. Full details of the synthesis of **6** and **7** and their experimental examination are provided. The supplementary data associated with this article can be found in the online version at doi:

The synthesis of the modified alkylation subunit^{19,20} began with treatment of 2-hydroxy-3-methoxy-5-nitrobenzaldehyde (**8**) with dimethylthiocarbamoyl chloride to afford the desired carbamothioate **9** (2 equiv DABCO, 1.5 equiv dimethylthiocarbamoyl chloride, DMF, 50-60 °C, 2 h, 91%). Compound **9** was thermally rearranged to provide **10** (toluene, 110 °C, 12 h, 95%) and the dimethylformamide group was removed (4 M NaOH, then 20% HCl, MeOH, 100 °C, 5 h, 90%) to afford the free thiol **11**. Alkylation of **11** with methyl bromoacetate followed by cyclization afforded benzothiophene **12** (1.5 equiv BrCH₂CO₂Me, 1.3 equiv K₂CO₃, 60 °C, 12 h, 98%). Deprotection of the methyl ether enlisting AlCl₃ (**13**, 0.14 equiv, CH₂Cl₂, 40 °C, 32 h, 89%) was followed by protection of the free phenol as its benzyl ether **14** (1.2 equiv benzyl bromide, 1.2 equiv K₂CO₃, acetone, 60 °C, 3.5 h, 73%). The aryl nitro group was reduced to the corresponding amine **15** (3 equiv Fe, 0.6 equiv NH₄Cl, MeOH/H₂O, 100 °C, 4 h, 87%) and the resulting aniline was protected to provide **16** using Boc₂O (5 equiv, THF, 23 °C, 12 h, 53%). Regioselective C4-iodination using *N*-iodosuccinimide (1.1 equiv, 1.1 equiv H₂SO₄, MeOH/THF, 23 °C, 4 h, 90%) afforded **17**, which was alkylated with 1,3-dichloropropene (2 equiv, 3 equiv NaH, DMF, 0 °C, 4 h, 84%) to afford **18**. The final ring of the alkylation subunit was constructed using a tris(trimethylsilyl)silane-mediated 5-*exo-trig* aryl radical-alkene cyclization (0.9 equiv TTMS, 0.2 equiv AIBN, benzene, 80 °C, 4 h, 74%) to afford **19**.²¹ Treatment of **19** with Pd(OH)₂ under an atmosphere of hydrogen gas (Pd (OH)₂, 1 atm H₂ gas, THF, 23 °C, 24 h, 75%) effectively cleaved the benzyl ether protecting group, affording **20**. Resolution of **20** into its enantiomers was possible at this stage using a ChiralCel OD semi-preparative HPLC column (2×25 cm, 2% *i*-PrOH/hexane, 7 mL/min, α = 1.24).²² Spirocyclization was accomplished upon treatment of **20** with DBU (1.3 equiv DBU, MeCN, 23 °C, 2.5 h, 54%) to afford **6** (Scheme 1, natural enantiomer shown).

Boc deprotection of **20** (4 N HCl/EtOAc, 23 °C, 1.5 h) followed by direct coupling of the resulting indoline hydrochloride salt with 5,6,7-trimethoxyindole-2-carboxylic acid²³ (**21**, 1.1 equiv, 3 equiv EDCI, DMF, 23 °C, 1.5 h, 61%) afforded **22** (Scheme 2, natural enantiomer shown) that was spirocyclized under mild conditions (saturated aqueous NaHCO₃, DMF, 57%) to afford **7**.

The results of the examination of *N*-Boc-CTI and the corresponding duocarmycin SA analogue in an L1210 cytotoxic assay are summarized in Table 1 along with the results of the comparison duocarmycin SA derivatives. Both enantiomers of the CTI-based analogues displayed cytotoxic activity (L1210) nearly identical to or slightly more potent than their DSA counterparts. The natural enantiomer of CTI-TMI (**7**, IC₅₀ = 7 pM) exhibited activity slightly more potent than that of duocarmycin SA (**1**, IC₅₀ = 10 pM). The unnatural enantiomer of **7** exhibited the 10-fold loss of activity (IC₅₀ = 60 pM) compared to the natural enantiomer and characteristic of duocarmycin SA itself. The Boc derivatives **6** exhibited nearly identical activity to that of *N*-Boc-DSA (**5**), with the unnatural enantiomers being 10-fold less potent than the natural enantiomers.

The DNA alkylation selectivity of the new analogues was examined within a 150 base-pair segment of DNA utilized and described previously (w794).²⁴ The alkylation site identification and the assessment of the relative selectivity among the available sites were obtained by thermally-induced strand cleavage of the singly 5'-end-labeled duplex DNA after exposure to the compounds as detailed.⁵⁻⁸ Figure 3 illustrates the alkylation selectivity of both (+)- and *ent*-(-)-CTI-TMI (**7**) alongside (+)- and *ent*-(-)-duocarmycin SA. Satisfyingly, each enantiomer of **7** alkylated the same site as its duocarmycin SA counterpart, displaying the same characteristic and enantiomerically distinguishable selectivity. The natural enantiomer, (+)-**7**, alkylated DNA with an efficiency not distinguishable from (+)-duocarmycin SA, (+)-**1**, and appreciable alkylation was seen at concentrations of 10⁻⁶ M (not shown). Like duocarmycin SA, the unnatural enantiomer of **7** proved less efficient at alkylating DNA than its natural enantiomer, and both unnatural enantiomers alkylated the same major site.

The CTI alkylation subunit was examined to establish whether the magnitude of the effects observed with the MeCTI alkylation subunit derived from a single atom replacement in the alkylation subunit of CC-1065 would be similarly observed with duocarmycin SA. The work presented herein demonstrates that replacing a pyrrole NH of the alkylation subunit of duocarmycin SA with a sulfur atom maintains or slightly enhances the biological potency of the natural product, but not to the extent observed with MeCTI. Additionally, CTI-TMI alkylated DNA in a fashion identical to duocarmycin SA, exhibiting the characteristic enantiomeric selectivities and distinguishable enantiomeric efficiencies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the financial support of the National Institutes of Health (CA041986) and the Skaggs Institute for Chemical Biology. KSM, JPL, and WMR are Skaggs Fellows.

References and notes

1. Ichimura M, Ogawa T, Takahashi K, Kobayashi E, Kawamoto I, Yasuzawa T, Takahashi I, Nakano H. J. Antibiot 1990;43:1037. [PubMed: 2211354]
2. Takahashi I, Takahashi K, Ichimura M, Morimoto M, Asano K, Kawamoto I, Tomita F, Nakano H. J. Antibiot 1988;41:1915. [PubMed: 3209484]
3. (a) Igarashi Y, Futamata K, Fujita T, Sekine A, Senda H, Naoki H, Furumai T. J. Antibiot 2003;56:107. [PubMed: 12715869] Structure revision: (b) Tichenor MS, Kastrinsky DB, Boger DL. J. Am. Chem. Soc 2004;126:8396. [PubMed: 15237994]
4. Martin DG, Biles C, Gerpheide SA, Hanka LJ, Krueger WC, McGovren JP, Mizesak SA, Neil GL, Stewart JC, Visser J. J. Antibiot 1981;34:1119. [PubMed: 7328053]
5. Duocarmycin SA: Boger DL, Johnson DS, Yun W. J. Am. Chem. Soc 1994;116:1635.
6. Yatakemycin: (a) Parrish JP, Kastrinsky DB, Wolkenberg SE, Igarashi Y, Boger DL. J. Am. Chem. Soc 2003;125:10971. [PubMed: 12952479] (b) Trzupek JD, Gottesfeld JM, Boger DL. Nature Chem. Biol 2006;2:79. [PubMed: 16415862] (c) Tichenor MS, Trzupek JD, Kastrinsky DB, Shiga F, Hwang I, Boger DL. J. Am. Chem. Soc 2006;128:15683. [PubMed: 17147378] (d) Tichenor MS, MacMillan KS, Trzupek JD, Rayl TJ, Hwang I, Boger DL. J. Am. Chem. Soc 2007;129:10858. [PubMed: 17691783]
7. CC-1065: (a) Hurley LH, Lee C-S, McGovren JP, Warpehoski MA, Mitchell MA, Kelly RC, Aristoff PA. Biochemistry 1988;27:3886. [PubMed: 3408734] (b) Hurley LH, Warpehoski MA, Lee C-S, McGovren JP, Scahill TA, Kelly RC, Mitchell MA, Wicnienski NA, Gebhard I, Johnson PD, Bradford VS. J. Am. Chem. Soc 1990;112:4633. (c) Boger DL, Johnson DS, Yun W, Tarby CM. Bioorg. Med. Chem 1994;2:115. [PubMed: 7922122] (d) Boger DL, Coleman RS, Invergo BJ, Sakya SM, Ishizaki T, Munk SA, Zarrinmayeh H, Kitos PA, Thompson SC. J. Am. Chem. Soc 1990;112:4623.
8. Duocarmycin A: (a) Boger DL, Ishizaki T, Zarrinmayeh H, Munk SA, Kitos PA, Suntornwat O. J. Am. Chem. Soc 1990;112:8961. (b) Boger DL, Ishizaki T, Zarrinmayeh H. J. Am. Chem. Soc 1991;113:6645. (c) Boger DL, Yun W, Terashima S, Fukuda Y, Nakatani K, Kitos PA, Jin Q. Bioorg. Med. Chem. Lett 1992;2:759. (d) Boger DL, Yun W. J. Am. Chem. Soc 1993;115:9872. (e) Boger DL, Wysocki RJ, Ishizaki T. J. Am. Chem. Soc 1990;112:5230. (f) Boger DL, Ishizaki T, Zarrinmayeh H. J. Org. Chem 1990;55:4499. (g) Boger DL, McKie JA, Nishi T, Ogiku T. J. Am. Chem. Soc 1997;119:311.
9. Reviews: (a) Boger DL, Johnson DS. Angew. Chem. Int. Ed. Engl 1996;35:1438. (b) Boger DL. Acc. Chem. Res 1995;28:20. (c) Boger DL, Johnson DS. Proc. Natl. Acad. Sci. U.S.A 1995;92:3642. [PubMed: 7731958] (d) Boger DL, Garbaccio RM. Acc. Chem. Res 1999;32:1043. (e) Tichenor MS, Boger DL. Natural Prod. Rep 2008;25:220. (f) MacMillan KS, Boger DL. J. Med. Chem 2009;52:5771. [PubMed: 19639994]

10. Warpehoski MA, Gebhard I, Kelly RC, Krueger WC, Li L, McGovern JP, Praire MD, Wieniensi N, Wierenga W. *J. Med. Chem* 1988;31:590. [PubMed: 3346875]
11. (a) Boger DL, Coleman RS, Invergo BJ, Zarrinmayeh H, Kitos PA, Thompson SC, Leong T, McLaughlin LW. *Chem.-Biol. Interact* 1990;73:29. [PubMed: 2406033] (b) Boger DL, Zarrinmayeh H, Munk SA, Kitos PA, Suntornwat O. *Proc. Natl. Acad. Sci. USA* 1991;88:1431. [PubMed: 1847523] (c) Boger DL, Munk SA, Zarrinmayeh H. *J. Am. Chem. Soc* 1991;113:3980. (d) Boger DL, Johnson DS. *J. Am. Chem. Soc* 1995;117:1443. (e) Boger DL, Zhou J, Cai H. *Bioorg. Med. Chem* 1996;4:859. [PubMed: 8818235]
12. (a) Boger DL, Bollinger B, Hertzog DL, Johnson DS, Cai H, Mesini P, Garbaccio RM, Jin Q, Kitos PA. *J. Am. Chem. Soc* 1997;119:4987. (b) Boger DL, Hertzog DL, Bollinger B, Johnson DS, Cai H, Goldberg J, Turnbull P. *J. Am. Chem. Soc* 1997;119:4977.
13. (a) Boger DL, Garbaccio RM. *Bioorg. Med. Chem* 1997;5:263. [PubMed: 9061191] (b) Ambroise Y, Boger DL. *Bioorg. Med. Chem. Lett* 2002;12:303. [PubMed: 11814783] (c) Boger DL, Santillan A Jr. Searcey M, Jin Q. *J. Am. Chem. Soc* 1998;120:11554.
14. Reviews: (a) Wolkenberg SE, Boger DL. *Chem. Rev* 2002;102:2477. [PubMed: 12105933] (b) Tse WC, Boger DL. *Chem. Biol* 2004;11:1607. [PubMed: 15610844] (c) Tse WC, Boger DL. *Acc. Chem. Res* 2004;37:61. [PubMed: 14730995]
15. (a) Boger DL, Ishizaki T. *Tetrahedron Lett* 1990;31:793. (b) Boger DL, Munk SA, Ishizaki T. *J. Am. Chem. Soc* 1991;113:2779. (c) Boger DL, Yun W. *J. Am. Chem. Soc* 1994;116:5523. (d) Boger DL, Munk SA. *J. Am. Chem. Soc* 1992;114:5487. (e) Boger DL, Mesini P, Tarby CM. *J. Am. Chem. Soc* 1994;116:6461. (f) Boger DL, McKie JA, Cai H, Cacciari B, Baraldi PG. *J. Org. Chem* 1996;61:1710. [PubMed: 11667041] (g) Boger DL, Han N, Tarby CM, Boyce CW, Cai H, Jin Q, Kitos PA. *J. Org. Chem* 1996;61:4894. (h) Boger DL, Turnbull P. *J. Org. Chem* 1997;62:5849. (i) Boger DL, Turnbull P. *J. Org. Chem* 1998;63:8004. (j) Boger DL, Garbaccio RM, Jin Q. *J. Org. Chem* 1997;62:8875. (k) Boger DL, Wolkenberg SE, Boyce CW. *J. Am. Chem. Soc* 2000;122:6325. (l) Ellis DA, Wolkenberg SE, Boger DL. *J. Am. Chem. Soc* 2001;123:9299. [PubMed: 11562212] (m) Boger DL, Santillan A Jr. Searcey M, Brunette SR, Wolkenberg SE, Hedrick MP, Jin Q. *J. Org. Chem* 2000;65:4101. [PubMed: 10866627] (n) Boger DL, Hughes TV, Hedrick MP. *J. Org. Chem* 2001;66:2207. [PubMed: 11281757] (o) MacMillan KS, Boger DL. *J. Am. Chem. Soc* 2008;130:16521. [PubMed: 19554689] (p) MacMillan KS, Nguyen T, Hwang I, Boger DL. *J. Am. Chem. Soc* 2009;131:1187. [PubMed: 19154178]
16. (a) Parrish JP, Hughes TV, Hwang I, Boger DL. *J. Am. Chem. Soc* 2004;126:80. [PubMed: 14709069] (b) Parrish JP, Trzupek JD, Hughes TV, Hwang I, Boger DL. *Bioorg. Med. Chem* 2004;12:5845. [PubMed: 15498660]
17. Tichenor MS, MacMillan KS, Stover JS, Wolkenberg SE, Pavani MG, Zanella L, Zaid AN, Spalluto G, Rayl TJ, Hwang I, Baraldi PG, Boger DL. *J. Am. Chem. Soc* 2007;129:14092. [PubMed: 17948994]
18. (a) Muratake H, Okabe K, Takahashi M, Tonegawa M, Natsume M. *Chem. Pharm. Bull* 1997;45:799. (b) Mohamadi F, Spees MM, Staten GS, Marder P, Kipka JK, Johnson DA, Boger DL, Zarrinmayeh H. *J. Med. Chem* 1994;37:232. [PubMed: 8295210] (c) Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Boyce CW, Boger DL. *Bioorg. Med. Chem. Lett* 1999;9:3087. [PubMed: 10560730]
19. (a) Boger DL, Machiya K. *J. Am. Chem. Soc* 1992;114:10056. (b) Boger DL, Machiya K, Hertzog DL, Kitos PA, Holmes D. *J. Am. Chem. Soc* 1993;115:9025. (c) Boger DL, Coleman RS. *J. Am. Chem. Soc* 1988;110:1321–4796. (d) Boger DL, Coleman RS. *J. Am. Chem. Soc* 1987;109:2717. (e) Boger DL, Mullican MD. *J. Org. Chem* 1984;49:4033. (f) Boger DL, Huter O, Mbiya K, Zhang M. *J. Am. Chem. Soc* 1995;117:11839.
20. Boger DL, Boyce CW, Garbaccio RM, Goldberg JA. *Chem. Rev* 1997;97:787. [PubMed: 11848889]
21. Boger DL, Boyce CW, Garbaccio RM, Searcey M. *Tetrahedron Lett* 1998;39:2227.
22. Boger DL, Yun W. *J. Am. Chem. Soc* 1994;116:7996.
23. Boger DL, Ishizaki T, Zarrinmayeh H, Kitos PA, Suntornwat O. *J. Org. Chem* 1990;55:4499.
24. Boger DL, Munk SA, Zarrinmayeh H, Ishizaki T, Haught J, Bina M. *Tetrahedron* 1991;47:2661.

Figure 1.
Natural products.

Figure 2.
Duocarmycin SA analogues.

Scheme 1.

Scheme 2.

Figure 3.

Thermally-induced strand cleavage of w794 DNA (144 bp, nucleotide no. 5238–138) after DNA–agent incubation with duocarmycin SA and CTI-TMI (24 h, 23 °C), removal of unbound agent by EtOH precipitation and 30 min thermolysis (100 °C), followed by denaturing 8% PAGE and autoradiography. Lane 1, control DNA; lanes 2–5, Sanger G, C, A, and T sequencing standards; lane 6, (+)-duocarmycin SA (**1**, 1×10^{-5} M); lane 7, (–)-duocarmycin SA (1×10^{-5} M); lanes 8 and 9, (+)-CTI-TMI and *ent*-(–)-CTI-TMI (**7**, 1×10^{-5} M).

Table 1

In Vitro Cytotoxic Activity, L1210

Compound	IC ₅₀ (pM)
(+)- 5 , (+)- <i>N</i> -Boc-DSA	6000
(-)- 5 , <i>ent</i> -(+)- <i>N</i> -Boc-DSA	60000
(+)- 6 , (+)- <i>N</i> -Boc-CTI	6000
(-)- 6 , <i>ent</i> -(+)- <i>N</i> -Boc-CTI	55000
(+)- 1 , (+)-duocarmycin SA	10
(-)- 1 , <i>ent</i> -(+)-duocarmycin SA	100
(+)- 7 , (+)-CTI-TMI	7
(-)- 7 , <i>ent</i> -(+)-CTI-TMI	60